Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06001658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

StatusRecruiting
PhasePhase 2
Started2024-07-08
View on ClinicalTrials.gov ↗

Amendment history

2025-12-01
Study Status, Contacts/Locations v7
Study sitescontacts updated at 1 of 1 site
2025-03-31
Study Status, Conditions v6
Re-verified, no change to tracked fields
2024-07-24
Study Status v5
Start dateestimated 2024-07→confirmed 2024-07-08
2024-06-24
Study Status v4
Primary completion date2028-05→2028-06
Completion date2028-05→2028-06
Start date2024-05→2024-07
2024-05-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
Show 2 earlier versions
2024-04-01
Study Status v2
Primary completion date2028-02→2028-05
Completion date2028-02→2028-05
Start date2024-02-29→2024-05
2024-01-03
Study Status v1
Primary completion date2027-12→2028-02
Completion date2027-12→2028-02
Start date2023-12→2024-02-29
2023-08-16
Original filing
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
Trial Details
NCT Number NCT06001658
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Merck Sharp & Dohme LLC
Conditions Billiary Track Cancer
Enrollment 27 participants
Start Date 2024-07-08
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-03